Genelux Corporation has unveiled its latest corporate presentation, highlighting their advancements in the field of immuno-oncology. The presentation focuses on Olvi-Vec, their late-stage clinical program aimed at platinum resensitization across multiple cancer indications. Notable ongoing trials include a pivotal Phase 3 trial for late-stage platinum-resistant/refractory ovarian cancer and Phase 2 and Phase 1b/2 trials for non-small cell lung cancer and small cell lung cancer, respectively. The presentation also emphasizes the potential of their CHOICETM Platform, housing over 500 novel vaccinia strains and 110+ transgenes, and their strategic partnership with Newsoara Biopharma for Greater China rights. The company is targeting a US launch in ovarian cancer and exploring broader market opportunities through systemic administration across various tumor types. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.